Sunday, November 17, 2024
- 3:00PM-4:30PM
-
Abstract Number: 1739
Adult and Pediatric Rheumatology Fellow Education on Temporomandibular Joint (TMJ) Arthritis in Patients with Juvenile Idiopathic Arthritis
Abstracts: Professional Education- 3:00PM-4:30PM
-
Abstract Number: 1744
Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom
Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)- 3:00PM-4:30PM
-
Abstract Number: 1714
Avoidable Hospitalizations by Persons with Rheumatoid Arthritis: A Population-Based Study Using Administrative Data
Abstracts: Epidemiology & Public Health II- 3:00PM-4:30PM
-
Abstract Number: 1731
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I- 3:00PM-4:30PM
-
Abstract Number: 1757
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Abstracts: SpA Including PsA – Treatment I- 3:00PM-4:30PM
-
Abstract Number: 1704
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation- 3:00PM-4:30PM
-
Abstract Number: 1723
Clustering Analysis with Unsupervised Machine Learning Process to Phenotype the Cardiovascular Risk of Patients with Rheumatoid Arthritis Beyond the 10-year Prediction Algorithm
Abstracts: Health Services Research I- 3:00PM-4:30PM
-
Abstract Number: 1754
Comparing the Molecular Landscape of the CAR-T Cell and Rituximab Mediated Remission in Systemic Lupus Erythematosus
Abstracts: SLE – Treatment I: Cellular Therapy- 3:00PM-4:30PM
-
Abstract Number: 1716
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Abstracts: Epidemiology & Public Health II- 3:00PM-4:30PM
-
Abstract Number: 1713
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Abstracts: Epidemiology & Public Health II- 3:00PM-4:30PM
-
Abstract Number: 1719
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Abstracts: Health Services Research I- 3:00PM-4:30PM
-
Abstract Number: 1705
Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome
Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation- 3:00PM-4:30PM
-
Abstract Number: 1727
Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
Abstracts: Immunological Complications of Medical Therapy- 3:00PM-4:30PM
-
Abstract Number: 1717
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Abstracts: Epidemiology & Public Health II- 3:00PM-4:30PM
-
Abstract Number: 1736
Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstitial Lung Disease Secondary to Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis: A Multi-Center Cohort Study with Propensity Score-Based Inverse Probability of Treatment Weighting